Drs. Bunick and Cameron discuss a case series recently published in the May 2025 issue of The Journal of Clinical and Aesthetic Dermatology that describes dupilumab-associated arthralgia in patients with atopic dermatitis that resolved after switching to tralokinumab. They discuss Dr. Cameron’s patient experience from the case series, clinical takeaways of the article, and how advancements in the understanding of patient endotypes can improve patient care in the future.
Time Stamps:
[00:00] Introduction
[01:49] Chapter 1: Reviewing AD endotypes and how patient endotypes influence treatment response
[03:09] Chapter 2: Real-world emergence of arthralgia as an adverse event associated with dupilumab
[05:09] Chapter 3: Dr. Cameron’s case—A patient with dupilumab-associated arthralgia and facial swelling with minor improvements after switching to lebrikizumab, with complete resolution upon switching to tralokinumab
[07:39] Chapter 4: Additional signs of Th-17 skewing in patients with atopic dermatitis
[08:09] Chapter 5: Advancing predictors of treatment response in patients with atopic dermatitis
Reference:
- Greenberg ABW, Shahriari M, Cameron, et al. Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series. J Clin Aesthet Dermatol. 2025;18(5):16–19.